Intravesical Lactobacillus to Reduce Urinary Symptoms After Spinal Cord Injury
Key facts
- Who runs it
- Medstar Health Research Institute
- Where
- Washington D.C., United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 182 people enrolled
- Started
- 1 Jun 2020
- Ended
- 14 Feb 2025
- Type of study
- Interventional, 2 groups
- Treatments tested
- Culturelle 10 Billion CFU Capsule (2 doses)
- Culturelle 10 Billion CFU Capsule (4 doses)
- Record updated
- 3 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- SCI at least 1-year duration
- Neurogenic bladder
- Utilizing intermittent catheterization for bladder management
- Women must be premenopausal and not currently menstruating
- Community dwelling
Who cannot take part
- Sexual activity within the previous 72 hours
- Psychologic or psychiatric conditions influencing the ability to follow instructions
- Use of prophylactic antibiotics
- Instillation of intravesical antimicrobials to prevent UTI
- Use of oral or IV antibiotics within the past 2 weeks
- Participation in another study with which results could be confounded
Where in United States
- MedStar National Rehabilitation HospitalWashington D.C., United States
About the trial
What the trial wants to find out
The objectives of the proposed research among this population are: 1) to define clinically meaningful change (i.e. differentiating states of health and illness) with respect to urinary symptoms, urine inflammation, cultivable bacteria, and the urine ecosystem; and 2) to determine the optimal intravesical Lactobacillus RhamnosusGG (LGG®) dose to be used to reduce urinary symptoms in a future clinical trial.
The 2 groups in the trial
- Low Dosage GroupTreatment being tested
For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermittent catheter. Participants will receive 2 LGG capsules and will repeat this process the following day ("Low" dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (2 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion.
Treatment: Culturelle 10 Billion CFU Capsule (2 doses)
- High Dosage GroupTreatment being tested
For the LGG® instillation, participants will be instructed to mix the contents of 1 LGG capsule into 45 cc sterile 0.9% saline. After mixing, participants will draw up the 45cc liquid LGG mixture into a 60cc syringe and instill via the intermittent catheter. Participants will receive 4 LGG capsules and will repeat this process the following day twice for a total of four doses ("High" dose). Subjects will remain in the study for up to 29 months, with participation ending after one completed intervention (4 doses) and post-intervention assessments are complete. If urinary symptoms do not occur warranting instillation during the ensuing 29 months, participants will be asked to return any remaining kits (including LGG®). Participants will be instructed to complete the USQNB-IDC weekly until study completion.
Treatment: Culturelle 10 Billion CFU Capsule (4 doses)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 3 November 2026